Alkermes (ALKS) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Alkermes (ALKS) overview

Alkermes (ALKS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1,476m and operating profit of USD 254m; the year-end share price was 27.98 USD and market capitalisation was USD 4,634m. Alkermes is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Alkermes's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 1,819mFY 2025
Share price27.98 USDFY 2025 year end
RevenueUSD 1,476mFY 2025
Operating profitUSD 254mFY 2025
Net earningsUSD 242mFY 2025
Market capitalisationUSD 4,634mFY 2025 year end

About Alkermes

Alkermes is a biopharmaceutical company developing medicines in neuroscience. Its commercial products treat alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. The company also develops clinical and preclinical candidates for neurological disorders, and licenses proprietary technologies used in products commercialized by other pharmaceutical companies. It operates from Ireland, Massachusetts and Ohio.

Generate the Alkermes report

Alkermes is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Alkermes and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Alkermes

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.